Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

BACKGROUND: (V600)BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibitors (BRAFi + MEKi). Although the combination therapy has been shown to provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Davies, Jenny E, Tran, Thai Q, Reid, Michael A, Rosales, Kimberly R, Lowman, Xazmin H, Pan, Min, Moriceau, Gatien, Yang, Ying, Wu, Jun, Lo, Roger S, Kong, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490757/
https://www.ncbi.nlm.nih.gov/pubmed/26139106
http://dx.doi.org/10.1186/s12967-015-0581-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490757/
https://www.ncbi.nlm.nih.gov/pubmed/26139106
http://dx.doi.org/10.1186/s12967-015-0581-2

Ejemplares similares